129306-06-5

Basic information

• Product Name: (E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one
• Synonyms: (E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one;5-Azaspiro[2.4]heptane-4,7-dione, 5-(phenylmethyl)-, 7-oxime
• CAS NO: 129306-06-5
• Molecular Formula: C13H14N2O2
• Molecular Weight: 230.26246
• Mol File: 129306-06-5.mol

Chemical Properties

• Boiling Point: 490.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.34±0.1 g/cm3(Predicted)
• PKA: 11.24±0.20(Predicted)
• CAS DataBase Reference: (E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one(129306-06-5)
• EPA Substance Registry System: (E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one(129306-06-5)

Safety Data

• Hazardous Substances Data: 129306-06-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one is utilized as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique spiro structure and functional groups facilitate multiple synthetic pathways, making it a versatile building block in the development of new compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one serves as a promising candidate for drug discovery. Its distinctive chemical properties and potential biological activities position it as a valuable template for the design and synthesis of novel therapeutic agents, particularly in the areas of medicinal chemistry and drug development.
Used in Medicinal Chemistry:
(E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one is employed as a structural motif in medicinal chemistry to explore its potential as a pharmacophore or to understand its interactions with biological targets. Its unique features may contribute to the development of new drugs with improved efficacy and selectivity.
Used in Drug Development:
In drug development, (E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one may be leveraged to create new pharmaceutical entities with potential therapeutic applications. Its exploration in this field could lead to the discovery of innovative treatments for various diseases and conditions, enhancing the repertoire of available medications.

Upstream product

• 129306-04-3 5-benzyl-5-azaspiro[2.4]heptane-4,7-dione 
• 882-36-0 N-benzyl-3-oxobutanamide 
• 147011-39-0 1-acetyl-N-[benzyl]cyclopropane-1-carboxamide 
• 331443-52-8 N-benzyl-1-(2-bromoacetyl)cyclopropanecarboxamide 

Downstream Products

• 129306-07-6 5-benzyl-5-azaspiro[2.4]heptane-7-amine 
• 129306-13-4 5-phenylmethyl-N-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-7-amine 
• 152513-88-7 (7S)-5-aza-7-tert-butoxycarbonylaminospiro[2.4]heptan 
• 144282-35-9 5-benzyl-7(S)-amino-5-azaspiro[2,4]heptane 
• 1432056-70-6 5-benzyl-7(S)-tert-butoxycarbonylamino-5-azaspiro[2,4]heptane 

Relevant articles and documents

A 5-benzyl -7 (S)-tert-butoxycarbonylamino-5-azaspiro [2,4] heptane preparation method of

The invention discloses a preparation method for 5-benzyl-7(S)-t-butyloxycarborylamino-5-aza-spiro[2,4]heptane. The method comprises the following steps: reacting benzoylamide acetoacetate as a raw material with 1,2-dichloroethane to obtain 3-cyclopropyl benzoylamide acetoacetate, brominating 3-cyclopropyl benzoylamide acetoacetate by NBS (n-bromosuccinimide) to obtain 1-bromo-3-cyclopropyl benzoylamide acetoacetate, cyclizing under alkaline conditions to obtain 5-benzyl-5-aza-spiro[2,4]heptane-4,7-diketone, further reacting with hydroxylamine hydrochloride to form an oxime compound-4-oxo-5-benzyl-7-oximido-5-aza-spiro[2,4]heptane, reducing by NaBH4 and boron trifluoride diethyl etherate to obtain 5-benzyl-7-amino-5-aza-spiro[2,4]heptane, performing chiral resolution by a resolving agent-L-camphorsulfonic acid to obtain 5-benzyl-7(S)-amino-5-aza-spiro[2,4]heptane, and reacting with di-tert-butyl dicarbonate ester to obtain 5-benzyl-7(S)-t-butyloxycarborylamino-5-aza-spiro[2,4]heptane. According to the method, an intermediate body-carbonyl does not need protection, raw materials are easy to get, a process route is simple, and the method is suitable for industrial production.

Substituted alkynyl pyridine compounds and methods of use thereof, and use thereof

The invention provides a substituted alkynylpyridine compound with a structure represented by a formula (I) as described in the specification and a pharmaceutically acceptable salt and a medicinal preparation thereof. The compound is used for adjusting activity of protein kinase and adjusting intercellular or intracellular signal response. The invention also relates to a pharmaceutical composition including the compound provided by the invention and a method of applying the pharmaceutical composition in treating mammals, especially in treating highly proliferative diseases of the mankind.

SUBSTITUTED ALKYNYL PYRIDINE COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl pyridine compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Spiro compound

The present invention relates to spiro compounds of general formula I: STR1 wherein the substituents are herein below defined. The present invention relates to antibacterial spiro compounds which are of value as drugs for humans, veterinary drugs or drugs for use in fish culture or as preservatives, and to antibacterial compositions containing one or more of the same compounds as active ingredients.